Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Cyrille Hulin et al.|Nature Medicine|2024Cited by 109
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, Cyrille Touzeau et al.|Blood|2025Cited by 34
B01 VENETOCLAX TARGETED THERAPY in AL AMYLOIDOSIS PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE FRENCH AMYLOIDOSIS NETWORKMurielle Roussel, Arnaud Jaccard, Frank Bridoux et al.|HemaSphere|2023Cited by 5
Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis NetworkMurielle Roussel, Arnaud Jaccard, Michelle Pirotte et al.|Blood|2022Cited by 3
Debulking Conventional Chemotherapy before Treatment By Anti-BCMA Bispecific Antibody in Extramedullary and/or High Tumor Burden Relapsed/Refractory Multiple MyelomaThomas Chalopin, Salomon Manier, Hélène Demarquette et al.|Blood|2024Cited by 3